[ad_1]
This time, the good news came from vaccine researchers at the University of Oxford. They say the response to the Oxford University coronavirus vaccine in older people is ‘encouraging’. The researchers say this is a hopeful sign to save the lives of people in the age group 60 to 70 who are infected with the Covid-19 disease. The vaccine, manufactured in Oxford, is registered with the pharmaceutical multinational AstraZeneca.
The results of the second phase of the Oxford Ticker test were published Thursday in the scientific journal The Lancet, the BBC reported. It has been found that even in the age group 60 to 70 years, the immune response of this vaccine is good. In the second phase, the vaccine was administered experimentally to a total of 560 adult volunteers.
In the third phase, the Oxford vaccine is being experimentally applied on a larger scale and to more people, the researchers say. Britain’s Reuters news agency quoted the Oxford Vaccine Group as saying that whether the vaccine could stop the spread of the disease would be known before Christmas (December 25).
Andrew Pollard, Director of the Vaccine Group, said: “We just realized that the vaccine could not stop the spread of the disease. There is no rush in this regard. However, we have come very close and of course we will know. before Christmas.
The progress of three ticks has been reported recently before the Oxford tick. These are Pfizer-Bioentech, Sputnik, and Modern. Pfizer’s coronavirus (Covid-19) vaccine has been claimed to be up to 95 percent effective. It is stated that no significant side effects were observed in this vaccine. On the other hand, Moderna Inc., another pharmaceutical multinational in the United States, said last Monday that its vaccines are 94.5% effective in preventing corona. Russia claims its Sputnik vaccine is more than 90 percent effective.
[ad_2]
